Clinical Trials Directory

Trials / Completed

CompletedNCT02551497

Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects

Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Biogen · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This is a double-blind, randomised, placebo-controlled 3 period study to evaluate the interaction between a drug and CNV1014802 in healthy male and female subjects. It is planned to enrol 36 subjects.

Detailed description

This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen.

Conditions

Interventions

TypeNameDescription
DRUGCNV1014802

Timeline

Start date
2015-04-30
Primary completion
2016-08-16
Completion
2016-08-26
First posted
2015-09-16
Last updated
2017-10-16

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02551497. Inclusion in this directory is not an endorsement.